Proceedings of the Meningococcal Vaccine Strategy World Health Organization Satellite Meeting, 10 March 2004, Auckland, New Zealand

New Zealand Medical Journal

Volumn 117, Issue 1200, 2004, Pages

  Sexton, Kerry ^a   Lennon, Diana ^b   Oster, Philipp ^c   Aaberge, Ingeborg ^d   Martin, Diana ^e   Reid, Stewart ^f   Wong, Sharon ^b   O'Hallahan, Jane ^a  

^a MINISTRY OF HEALTH   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Chiron Vaccines ^*  (Italy)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^f Ropata Medical Centre   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ANAPHYLAXIS; BACTERIAL STRAIN; BRAIN DISEASE; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DATA ANALYSIS; DEATH; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPIDEMIC; FLACCID PARALYSIS; GROUPS BY AGE; HEALTH CARE FACILITY; HEALTH CARE PLANNING; HUMAN; INFANT; INJECTION SITE REACTION; IRRITABILITY; LICENSING; MENINGOCOCCOSIS; MUSCLE HYPOTONIA; NEISSERIA MENINGITIDIS; NEW ZEALAND; NORWAY; PREVENTIVE HEALTH SERVICE; RECIPIENT; SEIZURE; SIDE EFFECT; SYMPOSIUM; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION; IMMUNIZATION; IMMUNOLOGY; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; NEW ZEALAND;

EID: 14844305112     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Sexton K, Lennon D, Oster P, et al. The New Zealand Meningococcal Vaccine Strategy: A tailor-made vaccine to combat a devastating epidemic. N Z Med J. 2004:117(1200). URL: http://www.nzma.org.nz/journal/117-1200/1015
2. Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis. 1998;177:497-500.
3. Martin D, McDowell R. The Epidemiology of Meningococcal Disease in New Zealand in 2003. A report prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR); 2004. Available online. URL: http://www.moh.govt.nz/moh.nsf/0/c088f437895d6dc8cc256ed1000b2539? OpenDocument. Accessed August 2004.
4. Jeffries C, Lennon D, Stewart J, Martin D. Meningococcal disease in Auckland, July 1992 - June 1994. N Z Med J. 1999;112:115-7.
5. Martin D, McDowell R, Sneyd L, Baker M. The Epidemiology of Meningococcal Disease in New Zealand in 2002. A report prepared for the Ministry of Health by the New Zealand Institute of Environmental Science and Research Limited (ESR); 2003. Available online. URL: http://www.moh.govt.nz/moh.nsf/49ba80c00757b8804c256673001d47d0/ 10281de7aa1d2774cc256d65007c83d1?OpenDocument. Accessed August 2004.
6. Lystad A, Aasen S. The epidemiology of meningococcal disease in Norway 1975-91. NIPH Annals. 1991;14:57-65.
7. Ministry of Health, Chiron Corporation, University of Auckland. Strategy to control the New Zealand epidemic of serogroup B meningococcal disease by vaccination. 30 November 2003 Revision. Unpublished Report.
8. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol. 1996;143:1165-73.
9. Booth L, Naracott E, Greenslade J. Meningitis C immunisation is low among young people who are not in education. BMJ. 2000:11:12.
10. Immunisation Advisory Centre. Strategic Recommendations for MeNZB™ Immunisation Service: Delivery to Youth aged 16-19 years not in Formal Education. A report to the Ministry of Health, 2004. Unpublished Report.
11. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894-901.
12. Connolly M, Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. Epidemiol Infect. 1999;122:41-9.
13. Idänpään-Heikkilä I, Høiby EA, Chattopadhyay P, et al. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J Med Microbiol. 1995;43:335-43.
14. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, I: role of humoral antibodies. J Exp Med. 1969;129:1307-26.
15. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, II: Development of natural immunity. J Exp Med. 1969;129:1327-48.
16. Gotschlich EC, Goldschneider I, Artenstein, MS. Human immunity to the meningococcus, IV: immunogenicity of the group A and group C polysaccharides in human volunteers. J Exp Med. 1969;129:1367-84.
17. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20:S58-67.
18. Martin D, McCallum L, Glennie A, et al. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials and population studies. Vaccine. (in press).
19. Fredriksen JH, Rosenqvist E, Wedege E, et al. Production, characterization and control of MenB-Vaccine «Folkehelsa»:An outer membrane vesicle vaccine against group B meningococcal disease. NIPH Annals. 1991;14:67-79.
20. Personal communication, Dr I Aaberge, Norwegian Institute of Public Health, Norway, March 2004.
21. Bjune G, Høiby EA, Grønnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338:1093-96.
22. Bjune G, Grønnesby JK, Høiby EA, et al. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Annals. 1991;14(2):125-32.
23. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21:734-7.
24. Aavitsland P, Nokleby H, Fuglesang J, Bjune G. Report of the epidemiological investigation of serious demyelinating and inflammatory neurological diseases with onset in the period after serogroup B meningococcal vaccination. NIPH internal report, 2001.
25. Thornton V, Lennon D, Martin D, et al. Exploratory study (Phase I/II) in healthy adults of New Zealand epidemic strain meningococcal serogroup B OMV vaccine targeting the POR A protein P1.7b,4: beginning of epidemic control. Community Child Health Committee and Public Health Association of New Zealand Joint Study Day, Paediatric Society of NZ, Queenstown, August 2003. (poster)
26. Aaberge IS, Helland O, Oster P, et al. Immunogenicity and reactogenicity of Meningococcal group B OMV vaccine and Meningococcal group C conjugate vaccine given in combination. In: Caugant DA and Wedege E, editors. Abstracts of the 13th International Pathogenic Neisseria Conference, Oslo 2002. Nordberg Aksidenstrykkeri AS, Oslo, p62.
27. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine. 1995;13:821-9.
28. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Annals. 1991;14:195-207.
29. Milagres LC, Ramos SR, Saachi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun. 1994;62:4419-24.
30. Granoff D, Feavers I, Borrow R Meningococcal Vaccines. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 4th ed. Philadelphia :Elsevier; 2004. p959-87.